BioSpace News Archive

BioCapital

UM School of Medicine Researchers Receive Federal Funding to Rapidly Test New Treatments for COVID-19

Long-time Coronavirus Researcher Joins Collaboration to Rapidly Repurpose FDA-approved Drugs for COVID-19

June 18, 2020
·
5 min read
Drug Development

Roche’s Checkpoint Inhibitor Hits the Mark in Early Triple-Negative Breast Cancer Study

In a Phase III study, Genentech’s Tecentriq (atezolizumab) in combination with Celgene’s Abraxane followed by chemotherapy demonstrated a statistically significant and clinically meaningful improvement in treating patients with early triple-negative breast cancer.

June 18, 2020
·
2 min read
·
Alex Keown
Biotech Beach

Engrail Emerges with $32 Million and a Goal of Developing New Neurological Treatments

Vikram Sudarsan, president and chief executive officer of Engrail, said the latest strides made in the field of neuroscience have buoyed the hopes of investors such as NFLS in funding drug development in this area.

June 18, 2020
·
2 min read
·
Alex Keown
Drug Development

Biopharma Update on the Novel Coronavirus: June 19

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 19, 2020.

June 18, 2020
·
4 min read
·
BioSpace Editorial Staff
Policy

Pharma Industry Wins Appeal Over Price Disclosures in Commercials

The U.S. Court of Appeals upheld a ruling that the Trump administration does not have the legal authority to mandate that drug companies disclose the list price of medications in television advertisements.

June 18, 2020
·
2 min read
·
Alex Keown
Pharm Country

Can CAR-T Cells Be Used to Treat Diseases like Diabetes and Fibrosis?

New research out of the Memorial Sloan Kettering Cancer Center suggests the genetically engineered immune cells can be used to treat diseases of senescence, which could include fibrotic liver disease, atherosclerosis, and diabetes.

June 18, 2020
·
3 min read
·
Mark Terry
Drug Development

New Study Shows ‘Nanosponges’ May Help Neutralize the Coronavirus

A new study published on Wednesday in the journal Nano Letters showed that cellular nanosponges may be able to inhibit SARS-CoV-2 infectivity within the body, ultimately neutralizing the virus.

June 18, 2020
·
3 min read
·
Krystle Vermes
Drug Development

Gilead to Test Antiviral Drug Remdesivir in Pediatric Patients with COVID-19

The company announced it planned to soon start enrolling an open-label, single-arm Phase II/III clinical trial of remdesivir in about 50 pediatric patients with moderate-to-severe COVID-19, including newborns through adolescents.

June 18, 2020
·
3 min read
·
Mark Terry
BioForest

Research Roundup: Predicting Susceptibility to COVID-19 and More

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

June 18, 2020
·
4 min read
·
Mark Terry
Business

BioSpace Movers & Shakers, June 19

Biopharma and life sciences companies bolster their executive leadership teams and boards with these Movers & Shakers.

June 18, 2020
·
7 min read
·
Alex Keown